UPDATE: (Aug. 2018) – The U.S. Food & Drug Administration have release an official “risk warning” regarding a rare but extremely serious, life-threatening condition associated with SGLT-2 Inhibitors, including Invokana, Jardiance, and Farxiga. “Fournier’s gangrene” is an necrotizing infection that affects the tissue, muscles, fat, nerves and blood vessels of the perineum; the area around/between the genitals and the rectum. The condition can quickly worsen and result in death.
If you or a loved one were hospitalized for renal failure, ketoacidosis, suffered a heart attack or stroke, required a leg, foot or toe amputation, or been diagnosed with “Fournier’s gangrene” while taking Jardiance or Farxiga, contact us online or call us at 1-866-252-3535.
UPDATE: (Aug. 2018) – Another medical study has found that SGLT-2 Inhibitors like Jardiance and Farxiga significantly increase the risk a user will have to undergo a lower limb amputation compared with older drugs such as Metformin.
MedPage Today | Aug. 3, 2018 | By Kristen Monaco
Farxiga and Jardiance are part of a new class of diabetes drugs that also includes Invokana. These diabetes drugs, called SGLT2 Inhibitors, are already causing a plethora of problems with the diabetics who use them.
If you or a loved one has taken Invokana, Farxiga, or Jardiance and been hospitalized with ketoacidosis, urosepsis, kidney damage and/or renal failure, have undergone a ‘lower-limb’ amputation, or have been diagnosed with “Fournier’s gangrene”, contact us online or call 1-866-252-3535 for a free consultation.